Cargando…

Insulin Receptor Antibody–Sulfamidase Fusion Protein Penetrates the Primate Blood–Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type A Cells

[Image: see text] Mutations in the lysosomal enzyme, N-sulfoglucosamine sulfohydrolase (SGSH), also called sulfamidase, cause accumulation of lysosomal inclusion bodies in the brain of children born with mucopolysaccharidosis type IIIA, also called Sanfilippo type A syndrome. Enzyme replacement ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boado, Ruben J., Lu, Jeff Zhiqiang, Hui, Eric Ka-Wai, Pardridge, William M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137762/ https://www.ncbi.nlm.nih.gov/pubmed/24949884 http://dx.doi.org/10.1021/mp500258p

Ejemplares similares

Pharmacokinetics and Safety in Rhesus Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery
por: Pardridge, William M., et al.
Publicado: (2009)

Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery
por: Boado, Ruben J., et al.
Publicado: (2019)

Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme
por: Hahn, Andreas, et al.
Publicado: (2022)

The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier
por: Boado, Ruben J., et al.
Publicado: (2011)

Enhancing the Therapeutic Potential of Sulfamidase for the Treatment of Mucopolysaccharidosis IIIA
por: Sorrentino, Nicolina Cristina, et al.
Publicado: (2019)

Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial
por: Giugliani, Roberto, et al.
Publicado: (2018)

Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA
por: Sidhu, Navdeep S., et al.
Publicado: (2014)

Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy
por: Chen, Yonghong, et al.
Publicado: (2018)

Kinetics of Blood–Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor
por: Pardridge, William M.
Publicado: (2021)

Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice
por: Sun, Jiahong, et al.
Publicado: (2019)

IgG Fusion Proteins for Brain Delivery of Biologics via Blood–Brain Barrier Receptor-Mediated Transport
por: Boado, Ruben J.
Publicado: (2022)

Treatment of Parkinson’s disease with biologics that penetrate the blood–brain barrier via receptor-mediated transport
por: Pardridge, William M.
Publicado: (2023)

Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor
por: Pardridge, William M., et al.
Publicado: (2021)

Mortality in patients with Sanfilippo syndrome
por: Lavery, Christine, et al.
Publicado: (2017)

Natural history of Sanfilippo syndrome in Spain
por: Delgadillo, Verónica, et al.
Publicado: (2013)

Sanfilippo syndrome: causes, consequences, and treatments
por: Fedele, Anthony O
Publicado: (2015)

Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier
por: Pardridge, William M.
Publicado: (2023)

How close are we to therapies for Sanfilippo disease?
por: Gaffke, Lidia, et al.
Publicado: (2017)

Is the eye a window to the brain in Sanfilippo syndrome?
por: Beard, Helen, et al.
Publicado: (2020)

Sanfilippo syndrome: consensus guidelines for clinical care
por: Muschol, Nicole, et al.
Publicado: (2022)

Economic Burden of Sanfilippo Syndrome in the United States
por: Ashby, Frederick, et al.
Publicado: (2023)

Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice
por: Gustavsson, Susanne, et al.
Publicado: (2019)

Impact of chemical modification of sulfamidase on distribution to brain interstitial fluid and to CSF after an intravenous administration in awake, freely-moving rats
por: Janson, Juliette, et al.
Publicado: (2019)

Prevalence of antibodies to ganglioside and Hep 2 in Gaucher, Niemann – Pick type C and Sanfilippo diseases
por: Dimitriou, Evangelia, et al.
Publicado: (2019)

Reply to Sanfilippo et al. and to Caviedes et al.
por: Arachchillage, Deepa J., et al.
Publicado: (2021)

Sanfilippo Syndrome: Optimizing Care with a Multidisciplinary Approach
por: Cyske, Zuzanna, et al.
Publicado: (2022)

Biochemical diagnosis of Sanfilippo disorder types A and B
por: Nosier, Soha S., et al.
Publicado: (2023)

Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)
por: Valstar, Marlies J, et al.
Publicado: (2011)

Epidemiology of Sanfilippo syndrome: results of a systematic literature review
por: Zelei, Tamás, et al.
Publicado: (2018)

Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III)
por: Muschol, Nicole M., et al.
Publicado: (2019)

Sanfilippo Syndrome: Molecular Basis, Disease Models and Therapeutic Approaches
por: Benetó, Noelia, et al.
Publicado: (2020)

A case report of Sanfilippo syndrome – the long way to diagnosis
por: Lorenz, Delia, et al.
Publicado: (2022)

An immune deficient mouse model for mucopolysaccharidosis IIIA (Sanfilippo syndrome)
por: Pollock, Kari, et al.
Publicado: (2023)

Molecular Bases of Neurodegeneration and Cognitive Decline, the Major Burden of Sanfilippo Disease
por: Heon-Roberts, Rachel, et al.
Publicado: (2020)

Caregivers' assessment of meaningful and relevant clinical outcome assessments for Sanfilippo syndrome
por: Porter, Katherine Ackerman, et al.
Publicado: (2022)

Unusual Clinical Manifestations in a Mexican Patient with Sanfilippo B Syndrome
por: Fernández-Hernández, Liliana, et al.
Publicado: (2022)

N-Substituted l-Iminosugars for the Treatment of Sanfilippo Type B Syndrome
por: De Pasquale, Valeria, et al.
Publicado: (2023)

Femoral Structure and Biomechanical Characteristics in Sanfilippo Syndrome Type-B Mice
por: Ashby, Frederick James, et al.
Publicado: (2023)

Advanced Blood–Brain Barrier Drug Delivery
por: Pardridge, William M.
Publicado: (2022)

A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II
por: Sonoda, Hiroyuki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jn2g26ttu1h4ca7o6me8jugpnj